ENVB — Enveric Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Enveric Biosciences Signs Non-Binding Term Sheets To Pursue The Exclusive Out-Licensing Of New Chemical Entities For Pharmaceutical And Non-Pharmaceutical Applications In Joint Disease
Brief: Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered By Non-Binding Term Sheets
Enveric Biosciences rises on deals to out-license three drug compounds
Brief: Enveric Biosciences Signs Non-Binding Term Sheets To Pursue The Exclusive Out-Licensing Of Three Classes Of Compounds
U.S. STOCKS ON THE MOVE-Hyatt Hotels, Morningstar Inc, SunPower Corp
U.S. STOCKS ON THE MOVE-Universal Insurance, Rocket Companies, Legend Biotech
Enveric Bio rises on plans to sell cannabinoid-related therapy patent
Brief: Enveric Biosciences To Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
Brief: Enveric Biosciences Inc Files Prospectus Relates To Resale Of Up To 2.2 Million Shares Of Common Stock By Selling Stockholders
Brief: Enveric Biosciences Updates Key Data Underpinning Selection Of Eb-003
Brief: Enveric Biosciences Announces Exercise Of Warrants And Issuance Of New Warrants In A Private Placement
Brief: Enveric Biosciences Selects EB-003 As Lead Drug Candidate From EVM301 Series
Brief: Enveric Biosciences Says Ongoing GLP Safety And Toxicology Program Of EB-373 Is Thus Far Proceeding On Time With Favorable Results
Brief: Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
Brief: Enveric Biosciences Says Co Entered Into Purchase Agreement And A Registration Rights Agreement With Lincoln Park Capital Fund
Brief: Enveric Biosciences Receives Notice Of Allowance From USPTO For Development Of C4-Carbonothioate-Substituted Tryptamine Derivatives For Novel Prodrug Of Psilocin
Brief: Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373
Brief: Enveric Biosciences says Expands Ip Portfolio With U.S. Patent For Novel Carboxylated Psilocybin Derivatives Supporting Evm301 Series Of Drug Candidates
Brief: Enveric Biosciences Files Provisional Patent Application For AI-Based Computational Methods For Identifying And Optimizing Novel Tryptamine Derivatives